文献速递儿童青少年精神

ADHD药物治疗的系统综述与剂量效应网络荟萃分析

Pharmacological interventions for ADHD: a systematic review and dose-effect network meta-analysis.
PubMed 文献 · Lancet Psychiatry · 2026-01-01

该研究系统检索并分析了164项RCT,其中113项纳入剂量效应网络荟萃分析,涵盖儿童青少年和成人。研究发现不同药物和年龄组的剂量效应模式不同,哌甲酯、安非他明和胍法辛在儿童青少年中分别至45mg/日、25mg/日、4mg/日疗效递增,成人安非他明约50mg/日以上出现平台期,且不良事件停药风险呈剂量依赖性增加。

要点

  • 儿童青少年哌甲酯、安非他明、胍法辛疗效分别在45、25、4mg/日达平台,更高剂量无额外获益证据。
  • 成人安非他明约50mg/日以上疗效平台,哌甲酯疗效无平台证据但数据稀疏。
  • 安非他明和哌甲酯的不良事件停药风险呈剂量依赖性增加,儿童与成人阈值不同。

核心结论

  • ADHD药物剂量效应因药物类别和年龄组而异,应避免治疗惰性和超许可剂量盲目递增。

研究设计与样本

  • 系统综述与剂量效应网络荟萃分析,纳入双盲RCT,评估5岁及以上符合标准化ADHD标准的口服单药治疗。
  • 共纳入164项RCT进行系统综述,其中113项RCT(成人45项,儿童青少年68项)纳入剂量效应网络荟萃分析。
  • 采用分层贝叶斯模型与限制性立方样条汇总剂量效应关联,主要结局为疗效,次要结局为因不良事件停药。

主要发现

  • 儿童青少年中,哌甲酯、安非他明和胍法辛的中位疗效分别至45mg/日、25mg/日和4mg/日递增,更高剂量无额外获益证据,但高剂量估计的可信区间宽。
  • 成人中,安非他明在约50mg/日以上疗效出现平台,哌甲酯疗效增加无平台证据,可能因数据稀疏。
  • 因不良事件停药概率呈剂量依赖性增加:安非他明在儿童青少年超过25mg/日、成人超过50mg/日;哌甲酯在成人超过50mg/日,儿童无明确剂量依赖风险。
  • 托莫西汀(固定剂量研究)和莫达非尼未发现剂量效应模式,多种敏感性分析证实结果稳健,未发现网络传递性异常。

关键数值与推荐

  • 儿童青少年:哌甲酯疗效递增至45mg/日,安非他明至25mg/日,胍法辛至4mg/日,更高剂量无额外获益证据。
  • 成人:安非他明疗效在约50mg/日以上出现平台;哌甲酯疗效增加无平台证据。
  • 因不良事件停药风险:安非他明儿童青少年超过25mg/日、成人超过50mg/日;哌甲酯成人超过50mg/日。

临床怎么用

  • 临床应基于年龄和药物类别进行剂量滴定,避免接受次优疗效而不调整剂量。
  • 不应无批判地超许可剂量递增,需权衡潜在危害与预期获益。
  • 研究结果可支持ADHD药物剂量的共享决策并指导临床指南制定。

局限性

  • 高剂量估计的可信区间宽,部分剂量效应估计不确定性大。
  • 成人哌甲酯疗效无平台证据可能因数据稀疏。
  • 各RCT种族或民族数据报告不一致。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Optimising the dosage of pharmacological treatments for ADHD is key to maximising their benefits, yet most clinical guidelines provide only limited information on this issue. Dose-effect relationships have not been comprehensively assessed across all ADHD medications and age groups, despite growing concerns about subtherapeutic prescribing. We aimed to estimate dose-effect curves for efficacy and tolerability of ADHD medications (stimulants and non-stimulants) across age groups. METHODS: We conducted a systematic review and dose-effect network meta-analysis of double-blind randomised controlled trials (RCTs) evaluating oral monotherapy (stimulants and non-stimulants) in individuals aged 5 years and older meeting standardised ADHD criteria. Studies involving genetic syndromes, treatment-resistant populations, or withdrawal-phase designs were excluded. We retrieved eligible studies from the MED-ADHD database, updated on Feb 17, 2025, without language restrictions. We included published and unpublished aggregated-level data. The primary outcome was efficacy (measured using validated clinical scales) and the secondary outcome was tolerability (discontinuation due to adverse events). Within-study bias was assessed with the Cochrane Risk of Bias Tool (version 2). We summarised dose-effect associations using a hierarchical Bayesian model with restricted cubic splines. Separate analyses were conducted for children or adolescents (aged <18 years) and adults (aged ≥18 years). The distribution of key effect modifiers was used to examine transitivity of the network. People with lived experience were involved in the conceptualisation and design of the study, and in the interpretation of the findings. The protocol was pre-registered on OSF. FINDINGS: Our 2017 search identified 9948 potential references for inclusion and our Feb 17, 2025 search identified 5148 references. Of these 15 096 references, 8467 were excluded after title and abstract screening, and a further 5862 references were excluded after a full-text read. Of the 767 remaining reports, 164 were included in the systematic review and 113 RCTs (45 in adults and 68 in children and adolescents) were included in the dose-effect network meta-analysis. The 68 RCTs on children and adolescents included 14 138 participants (9981 [70·6%] males and 4157 [29·4%] females) and the 45 RCTs on adults included 11 016 participants (5958 [54·0%] males and 5056 [46·0%] females). Data on ethnicity or race were inconsistently reported across RCTs. We found distinct dose-effect patterns by medication class and age group. In children and adolescents, methylphenidate, amphetamines, and guanfacine showed increasing median efficacy up to 45 mg/day, 25 mg/day and 4 mg/day, respectively, with no evidence of additional benefit at higher doses, although estimates at higher doses were characterised by wide credible intervals. In adults, amphetamines showed a plateau above approximatively 50 mg/day, whereas methylphenidate efficacy increased without evidence of a plateau, possibly due to sparse data. Dose-dependent increases in discontinuation probability due to adverse events were observed for amphetamines (above 25 mg/day for children and 50 mg/day for adults) and methylphenidate (above 50 mg/day for adults, with no clear dose-dependent risk for children). We found no evidence of dose-effect patterns for atomoxetine (in fixed-doses studies) and modafinil. Multiple sensitivity analyses confirmed the robustness of these findings. We found no evidence of intransitivity. INTERPRETATION: Our findings challenge both therapeutic inertia-accepting suboptimal response without further dose titration-and uncritical dose escalation beyond licensed limits, when potential harms outweigh expected benefits. Our findings can inform clinical guidelines and should support shared decision making regarding ADHD medication dosage. FUNDING: National Institute for Health and Care Research (NIHR303122).

来源:Lancet Psychiatry,查看原文。版权归原作者所有。

引用

  1. Nourredine M, Jurek L, Hamza T, et al. Pharmacological interventions for ADHD: a systematic review and dose-effect network meta-analysis. Lancet Psychiatry. 2026. PMID: 42134365. doi:10.1016/S2215-0366(26)00091-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。